She planned for a family, not for IVF Failure.

It’s time to introduce ReceptivaDx® Testing
Predictive Value of BCL6
Women Presenting with Unexplained Infertility (UI)

BCL6 Positive Rate
75%

BCL6 Negative Rate
25%

PROBABILITY OF LIVE BIRTH AFTER NEXT IVF TRANSFER
(Left Untreated)

11%

59%

“Common sense tells us that endometriosis is a major cause of subfertility, but women undergoing IVF are rarely diagnosed with this disease before treatment. This test provides an opportunity for couples to better understand the basis of their infertility and will provide more options and higher success rates.”

Bruce Lessey, MD, Ph.D. Greenville, SC
What is ReceptivaDx®?

ReceptivaDx® is the first test to measure BCL6 as a biomarker for all stages of endometriosis, the predominant finding in Unexplained Infertility (UI) and Unexplained Recurrent Pregnancy Loss (uRPL)\(^1,4\)

The Importance of ReceptivaDx® Testing

- Endometriosis is the predominant finding after laparoscopy in BCL6 positive patients\(^1\)
- A study of patients with prior history of failed IVF demonstrated improved pregnancy rates from 37% to 76% after undergoing laparoscopy\(^2\)
- ReceptivaDx® Panel offers 96% sensitivity and specificity for endometriosis via the BCL6 marker\(^1\)

Candidates for ReceptivaDx® Testing:

- Women with unexplained infertility
- Women with previous IVF failure
- Women with recurrent pregnancy loss
- Women with previous diagnosis of endometriosis
- Women seeking enhanced screening prior to any transfer attempts
- Women seeking re-testing after treatment of a prior positive BCL6 result

Join the growing list of over 100 IVF Centers around the world now using ReceptivaDx®

“The ReceptivaDx® test has given me the ability to diagnose endometriosis in patients with a simple biopsy. Being able to do this is life changing. Through this test, I’m able to give patients a diagnosis, explanation and most importantly an individualized protocol and path to successful pregnancy. There is no other test like this.”

Aimee Eyvazzadeh, M.D.
San Ramon, CA
GETTING STARTED

Collection Kits and Test Request Forms are available by calling customer service at 800-795-5385.

Overnight shipping materials and prepaid shipping labels are provided at no cost as part of our ReceptivaDx® Collection Kit.

International Customers must secure shipment to the US at their own expense. Please contact us via email at info@receptivadx.com for more information.

Test Fees & Payment Information:

The cost of the ReceptivaDx® Assay is $690 dollars (U.S.). This includes complete pathology analysis for the BCL6 marker. For clients seeking to add the Beta 3 Integrin biomarker, the price for the full panel is $790 dollars. Payment must be submitted at the time of sample submission. All major credit cards are accepted. CiceroDx does not bill or contract with insurance plans. A detailed receipt will be provided to patients for submission to payers and/or healthcare spending accounts.

Repeat Testing:

Follow-up or repeat submissions within 12 months of original biopsy are eligible for a $100 discount. Date of original biopsy is required.

Test Results:

Test results are available 3-4 business days after date of receipt in our lab. Reports are faxed to the ordering physician immediately after pathology sign-out occurs.

REFERENCES

1. Almquist et al., Fert Steril, in press, 2017


CiceroDx, Inc. is the exclusive licensed provider for BCL6 analysis on endometrial tissue. CiceroDx is dedicated to the transfer of new technologies to advance global healthcare for women. For more information, visit us on the web at www.cicerodx.com

www.receptivadx.com

800-795-5385